• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Medidata acquires Intelemage

Medidata acquires Intelemage

April 6, 2016
CenterWatch Staff

Medidata, a global provider of cloud-based solutions for clinical research in life sciences, has announced the acquisition of Intelemage, a global pioneer in medical image sharing and workflow management. Medidata will integrate Intelemage’s technology into its SaaS platform, the Medidata Clinical Cloud, offering customers an end-to-end solution to capture, manage and analyze medical imaging data. The transaction was completed in the second quarter of 2016.

Founded in 2007, Intelemage powers medical image file sharing in clinical trials as well as for hospitals, physicians, life sciences companies, research institutions and core labs. The company also provides tools for medical imaging data capture and workflow management. Currently operational in 85 countries and over 5,000 global locations, Intelemage’s technology enables clients to manage all imaging activities in a single environment, providing them with the highest level of control and access to data, performance metrics and other clinical resources. In just the last 12 months, Intelemage has processed 400 million images.

“Imaging technologies play a vital role in evaluating new therapies, allowing clinicians and sponsors to detect diseases, monitor outcomes and predict therapy responses,” said Tarek Sherif, Medidata’s chief executive officer. “Intelemage adds another dimension to the compelling value proposition that is making the Medidata Clinical Cloud an industry standard. We are excited to enter this fast-growing market with next-generation medical imaging capabilities, which—combined with the power of our platform—improve the design, speed, efficiency and analytical rigor of clinical trials, helping to get innovative treatments to patients faster.”

In acquiring Intelemage, Medidata is enhancing the capabilities of its cloud technology platform. Medidata technology has transformed clinical trial design and execution and has, to date, supported more than 11,000 clinical studies, 400,000 investigational sites and 2.8 million trial volunteers.

“Using Intelemage’s medical imaging technology has given us the ability to seamlessly capture data, streamline workflows and transfer imaging datasets securely, compliantly and reliably,” said Nicholas Wharton, co-founder and senior vice president of Medical Metrics, an Intelemage customer and partner since 2013 and a leading provider of imaging core lab services for global clinical trials of orthopedic, cardiovascular and neurovascular medical devices, drugs and biologics. “At a time when clinicians and sponsors are increasingly turning to imaging-based biomarkers to detect and monitor disease and to assess the effectiveness of therapies, it’s exciting to see Intelemage join Medidata. The Medidata platform is transforming clinical research and—with the addition of Intelemage’s cutting-edge capabilities for global image sharing and management—is poised to play an even more significant role in driving the kind of medical innovation that will improve the lives of patients around the world.”

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing